The ESTxENDS Trial- Substudy on the Metabolic Effects of Using Electronic Nicotine Delivery Systems (ENDS/Vaporizer/E-cig)

Cardiovascular Diseases Clinical Trial

— ESTxENDS  

Official title:

Substudy of Efficacy, Safety and Toxicology of Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation (ESTxENDS Trial)- the Metabolic Substudy of ESTxENDS

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03612336
• Other study ID #: 2017-02332b
• Status: Completed
• Phase: N/A
• Start date: July 16, 2018
• Est. completion date: August 31, 2023

Study information

• Verified date: November 2023
• Source: University of Bern
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

--> This is a substudy of the main ESTxENDS trial (NCT03589989). Metabolic outcomes should be considered secondary outcomes of the main smoking cessation outcome formulated in NCT03589989. Cardiovascular diseases (CVD) are a leading cause of death in cigarette smokers; quitting smoking is associated with reduced CVD. Cigarette smoking increases CVD through complex mechanisms, mostly on an increase in atherosclerosis and the effect appears unrelated to nicotine. Recently, electronic nicotine delivery systems (ENDS; also called vaporizer or electronic cigarette) have become popular with smokers who want to stop smoking. There is currently no evidence that ENDS use affects CVD outcomes. The nicotine contained in the e-liquids from ENDS has cardiovascular effects and the evidence about health effects mostly comes from studies on nicotine replacement therapy (NRT). These studies did not show an increased risk of CVD from NRTs. The ECLAT trial showed no difference in body weight, resting heart rate, or blood pressure between those who used ENDS or not. Two studies evaluated the short-term effects of ENDS on the cardiovascular system. One study suggested impairment in diastolic ventricular function with cigarettes and not with ENDS. Both ENDS and cigarettes increased diastolic blood pressure, potentially mediated through nicotine exposure, but an increased systolic blood pressure was found only in cigarette smokers. Other studies have suggested no changes in blood pressure in daily users of electronic cigarettes up to 1 year with some even a reduction in blood pressure among patients with hypertension. Interventions helping smokers quit have shown that quitting is associated with increased HDL-cholesterol, weight gain, higher blood glucose, and higher diabetes risk. No large randomized trials have tested the effect of ENDS on blood cholesterol and other markers of cardiovascular risk. This study will therefore test the efficacy of ENDS for cigarette smoking cessation, the safety of ENDS on adverse events and the effect of ENDS on health-related outcomes and exposure to inhaled chemicals. For the main ESTxENDS trial (NCT03589989), smokers motivated to quit smoking cigarettes will be included. Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants in the control group will receive smoking cessation counseling only. All participants will be followed over a 24-month period. Measurements of risk factors for cardiovascular diseases will be done at baseline and at 6, 12 and 24 months' follow-up.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1246
• Est. completion date: August 31, 2023
• Est. primary completion date: August 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Informed Consent as documented by signature
• Persons aged 18 or older
• Currently smoking 5 or more cigarettes a day for at least 12 months
• Willing to try to quit smoking within the next 3 months,
• Persons providing a valid phone number, a valid email address and/or a valid postal address.

Exclusion criteria:

• Known hypersensitivity or allergy to contents of the e-liquid
• Participation in another study with investigational drug within the 30 days preceding the baseline visit and during the present study where interactions are to be expected
• Women who are pregnant or breast feeding
• Intention to become pregnant during the course of the scheduled study intervention, i.e. within the first 6-months of the study
• Persons having used ENDS or tobacco heating systems regularly in the 3 months preceding the baseline visit
• Persons having used nicotine replacement therapy (NRT) or other medications with demonstrated efficacy as an aid for smoking cessation such as varenicline or bupropion within the 3 months preceding the baseline visit
• Persons who cannot attend the 6- month follow-up visit for any reason
• Cannot understand instructions delivered in person or by phone, or otherwise unable to participate in study procedures

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Smoking Cessation

Intervention

Other:
• ENDS (vaporizer/e-cig) and smoking cessation counseling
Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
• Smoking cessation counseling
Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.

Locations

Country	Name	City	State
Switzerland	University Clinic for General Internal Medicine, Bern University Hospital	Bern
Switzerland	Département de médecine interne, Hôpitaux universitaires de Genève	Geneva
Switzerland	Unisanté, Centre universitaire de médecine générale et santé publique, Université de Lausanne	Lausanne	Vaud
Switzerland	Lungenzentrum, Klinik für Pneumologie und Schlafmedizin, Kantonsspital St. Gallen	Saint Gallen
Switzerland	Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich	Zürich

Sponsors (8)

Lead Sponsor	Collaborator
University of Bern	Federal Office of Public Health, Switzerland, Krebsforschung Schweiz, Bern, Switzerland, State Hospital, St. Gallen, Swiss National Science Foundation, University of Geneva, Switzerland, University of Lausanne, University of Zurich

Country where clinical trial is conducted

Switzerland, 

References & Publications (10)

Aubin HJ, Farley A, Lycett D, Lahmek P, Aveyard P. Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ. 2012 Jul 10;345:e4439. doi: 10.1136/bmj.e4439. — View Citation

Benowitz NL, Fraiman JB. Cardiovascular effects of electronic cigarettes. Nat Rev Cardiol. 2017 Aug;14(8):447-456. doi: 10.1038/nrcardio.2017.36. Epub 2017 Mar 23. — View Citation

Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, Lawrence D, St Aubin L, Anthenelli RM. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med. 2018 May 1;178(5):622-631. doi: 10.1001/jamainternmed.2018.0397. — View Citation

Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, Polosa R. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One. 2013 Jun 24;8(6):e66317. doi: 10.1371/journal.pone.0066317. Print 2013. Erratum In: PLoS One. 2014;9(1). doi:10.1371/annotation/e12c22d3-a42b-455d-9100-6c7ee45d58d0. — View Citation

Farsalinos K, Cibella F, Caponnetto P, Campagna D, Morjaria JB, Battaglia E, Caruso M, Russo C, Polosa R. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. Intern Emerg Med. 2016 Feb;11(1):85-94. doi: 10.1007/s11739-015-1361-y. Epub 2016 Jan 9. — View Citation

Farsalinos KE, Tsiapras D, Kyrzopoulos S, Savvopoulou M, Voudris V. Acute effects of using an electronic nicotine-delivery device (electronic cigarette) on myocardial function: comparison with the effects of regular cigarettes. BMC Cardiovasc Disord. 2014 Jun 23;14:78. doi: 10.1186/1471-2261-14-78. — View Citation

Forey BA, Fry JS, Lee PN, Thornton AJ, Coombs KJ. The effect of quitting smoking on HDL-cholesterol - a review based on within-subject changes. Biomark Res. 2013 Sep 13;1(1):26. doi: 10.1186/2050-7771-1-26. — View Citation

Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, McAfee T, Peto R. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013 Jan 24;368(4):341-50. doi: 10.1056/NEJMsa1211128. — View Citation

Oncken CA, Litt MD, McLaughlin LD, Burki NA. Nicotine concentrations with electronic cigarette use: effects of sex and flavor. Nicotine Tob Res. 2015 Apr;17(4):473-8. doi: 10.1093/ntr/ntu232. — View Citation

Stein JH, Asthana A, Smith SS, Piper ME, Loh WY, Fiore MC, Baker TB. Smoking cessation and the risk of diabetes mellitus and impaired fasting glucose: three-year outcomes after a quit attempt. PLoS One. 2014 Jun 3;9(6):e98278. doi: 10.1371/journal.pone.0098278. eCollection 2014. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurements of risk factors for cardiovascular diseases (blood pressure)_1	Measurement of blood pressure	6 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (blood pressure)_2	Measurement of blood pressure	12 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (blood pressure)_3	Measurement of blood pressure	24 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (heart rate)_1	Measurement of heart rate	6 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (heart rate)_2	Measurement of heart rate	12 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (heart rate)_3	Measurement of heart rate	24 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (total cholesterol)_1	Measurement of total cholesterol	6 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (total cholesterol)_2	Measurement of total cholesterol	12 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (total cholesterol)_3	Measurement of total cholesterol	24 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (LDL-cholesterol)_1	Measurement of LDL-cholesterol	6 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (LDL-cholesterol)_2	Measurement of LDL-cholesterol	12 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (LDL-cholesterol)_3	Measurement of LDL-cholesterol	24 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (HDL-cholesterol)_1	Measurement of HDL-cholesterol	6 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (HDL-cholesterol)_2	Measurement of HDL-cholesterol	12 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (HDL-cholesterol)_3	Measurement of HDL-cholesterol	24 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (triglycerides)_1	Measurement of triglycerides	6 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (triglycerides)_2	Measurement of triglycerides	12 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (triglycerides)_3	Measurement of triglycerides	24 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (HbA1c)_1	Measurement of HbA1c for persons with diagnosed diabetes	6 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (HbA1c)_2	Measurement of HbA1c for persons with diagnosed diabetes	12 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (HbA1c)_3	Measurement of HbA1c for persons with diagnosed diabetes	24 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (creatinine)_1	Measurement of creatinine	6 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (creatinine)_2	Measurement of creatinine	12 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (creatinine)_3	Measurement of creatinine	24 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (waist circumference)_1	Measurement of waist circumference	6 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (waist circumference)_2	Measurement of waist circumference	12 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (waist circumference)_3	Measurement of waist circumference	24 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (body mass index, BMI)_1	Measurements of weight and height to report BMI in kg/m^2	6 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (body mass index, BMI)_2	Measurements of weight and height to report BMI in kg/m^2	12 months post quit date
Primary	Measurements of risk factors for cardiovascular diseases (body mass index, BMI)_3	Measurements of weight and height to report BMI in kg/m^2	24 months post quit date
Secondary	Changes in cardiovascular disease risk factors (blood pressure)	Measurement of blood pressure	Change from Baseline to 6,12, 24 months post quit date
Secondary	Changes in cardiovascular disease risk factors (heart rate)	Measurement of heart rate	Change from Baseline to 6,12, 24 months post quit date
Secondary	Changes in cardiovascular disease risk factors (total cholesterol)	Measurement of total cholesterol	Change from Baseline to 6,12, 24 months post quit date
Secondary	Changes in cardiovascular disease risk factors (LDL-cholesterol)	Measurement of LDL-cholesterol	Change from Baseline to 6,12, 24 months post quit date
Secondary	Changes in cardiovascular disease risk factors (HDL- cholesterol)	Measurement of HDL- cholesterol	Change from Baseline to 6,12, 24 months post quit date
Secondary	Changes in cardiovascular disease risk factors (triglycerides)	Measurement of triglycerides	Change from Baseline to 6,12, 24 months post quit date
Secondary	Changes in cardiovascular disease risk factors (HbA1c)	Measurement of HbA1c for persons with diagnosed diabetes	Change from Baseline to 6,12, 24 months post quit date
Secondary	Changes in cardiovascular disease risk factors (creatinine)	Measurement of creatinine	Change from Baseline to 6,12, 24 months post quit date
Secondary	Changes in cardiovascular disease risk factors (waist circumference)	Measurement of waist circumference	Change from Baseline to 6,12, 24 months post quit date
Secondary	Changes in cardiovascular disease risk factors (body mass index, BMI)	Measurements of weight and height to report BMI in kg/m^2	Change from Baseline to 6,12, 24 months post quit date
Secondary	Physical activity	Measured using the International Physical activity questionnaire (IPAQ). The short version (7 items) provides information on the time spent walking, in vigorous- and moderate-intensity activity and in sedentary activity.	6,12, 24 months post quit date
Secondary	Changes of physical activity	Measured using the International Physical activity questionnaire (IPAQ). The short version (7 items) provides information on the time spent walking, in vigorous- and moderate-intensity activity and in sedentary activity.	Change from Baseline to 6,12, 24 months post quit date